Smoking: additional burden on aging and death by unknown
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Tobacco smoking is a major cause of lung cancer. It has been suggested that there is an approximately linear
dose–response relationship between the number of cigarettes smoked per day and clinical outcome such as lung
cancer mortality. It has also been proposed that there is a greater increase in mortality at high doses when the
dose is represented by the duration of the smoking habit rather than the number of cigarettes. The multistep
carcinogenesis theory indicates that a greater increase in mortality rate at high doses is possible, as is the case
between aging and cancer, even though each dose–response relationship between a carcinogenic factor and a
carcinogenic step forward is linear. The high incidence of lung cancer after long-term smoking and the decreased
relative risk after smoking cessation suggests a similarity between the effects of smoking and aging. Prediction of
lung cancer risk in former smokers by simple integration of smoking effects with aging demonstrated a good
correlation with that estimated from the relative risk of the period of smoking cessation. In contrast to the smoking
period, there appears to be a linear relationship between smoking strength and cancer risk. This might arise if the
dose–response relationship between smoking strength and each carcinogenic step is less than linear, or the effects
become saturated with a large dose of daily smoking. Such a dose–response relationship could lead to relatively
large clinical effects, such as cardiovascular mortality, by low-dose tobacco smoke exposure, e.g., second-hand
smoking. Consideration of the dose–response of each effect is important to evaluate the risk arising from each
carcinogenic factor.
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Introduction – smoking as a human carcinogen
Smoking causes a variety of diseases including cancer. In
1981, Doll and Peto estimated that 30 % of all cancer
deaths were attributable to tobacco smoking [1]. This
estimation is basically similar in Japan, as the population
attributable fractions of cancer mortality related to
tobacco smoking in Japanese men and women in 2005
have been estimated to be 34.4 % and 6.2 %, respectively
[2]. Tobacco smoke contains many kinds of carcinogens.
The International Agency for Research on Cancer evalu-
ated and classified 16 compounds present in tobacco
smoke as Group 1 - carcinogenic to humans [3]. The
tumor promotion activity of tobacco smoke is also estab-
lished [3, 4].
Relationship between dose–response of each
carcinogenic step and clinical outcome
The simplest model to estimate the clinical consequence
of a carcinogenic factor, or dose–response relationship
between the factor such as tobacco smoking and cancer
mortality, is linear-no-threshold, while cancer emerges
after progressing through a number of steps in the car-
cinogenic process [5, 6]. When the dose–response rela-
tionship between a factor and each carcinogenic step,
such as initiation by mutation induction, is linear, the
clinical response is also linear at low doses, called “line-
arized multistage” [7]. This holds true regardless of
whether the factor affects a single or a number of
carcinogenic steps. However, this prediction is not
applicable at high doses. When the factor affects many
carcinogenic steps such as mutation induction and cell
growth, the clinical dose–response relationship is more
than linear, or a steeper increase in cancer incidence
with the increment in dose occurs, even when the dose–
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response relationship for each step is linear. It is indeed
a case of the factor “aging”, since cancer mortality gener-
ally increases almost logarithmically with increasing age.
In addition to the traditional Armitage-Doll multistage
model, there are many mathematical models to explain
the relationship between cancer incidence and age [8–13].
For smoking and smoking-related cancers such as lung
cancer, approximately linear dose–response relationships
have been observed in a number of epidemiological
studies when the dose was represented by the number of
cigarettes per day [14–19]. When the dose was repre-
sented by the duration of the smoking habit, a greater
than linear increment in incidence or mortality was re-
ported [20–22]. Because a life-long smoking habit can be
considered as a very high dose of carcinogenic factor, it is
possible that the duration of the smoking habit affects sev-
eral steps of carcinogenesis in a linear relationship, but
causes a higher incidence of cancer after long-term smok-
ing. Note that, if a factor affects only one step in a linear
dose–response relationship rather than multiple steps de-
scribed above, the incidence of cancer at a high dose is
dependent on which step is affected and the mechanism
of cancer induction, such that both a steep increment or a
plateau are possible.
Smoking as an aging accelerator
Naturally, cancer occurs during aging because activation
of steps in the carcinogenic process, such as mutation
induction and cell growth, increase during aging. To-
bacco smoking exhibits a tumor promoting effect as well
as induction of mutation, thus smoking induces a num-
ber of steps in carcinogenesis. Therefore, when smokers
stop smoking, the relative risk of developing cancer
gradually decreases compared with the risk in continu-
ing smokers, but it does not fall to the level of non-
smokers, since past smoking continues to have an effect
even after long-time smoking cessation. Most studies
have demonstrated that the risk in former smokers is far
lower than in continuing smokers but remains higher
than that in nonsmokers [15, 20–24]. There are several
reports concerning cancer risk prediction, from simple
approximation by regression equation to rather compli-
cated approaches, including validation of several mathem-
atical models [25–29]. If smoking affects all carcinogenic
steps in the same proportion to that of aging, the effects
of smoking can be simplified as an additional aging effect,
and risk prediction in continuing and former smokers
may be possible regardless of the cancer model. I exam-
ined such a simple explanation of smoking effects using
data reported by Peto et al. [20].
In considering lung cancer death, probability is as-
sumed to be determined by aging level x + a(s − l), where
x, s, l, and a are age, smoking period, lag time, and coef-
ficient of aging effect by smoking. The parameters a and
l were estimated from the former smoker’s age corre-
sponding to that of a continuing smoker (Table 1 and
Fig. 1). When the risk of nonsmokers and smokers were
approximated by a single polynomial equation, the highest
correlation was observed if smoking started at 11 years
old (Fig. 2). This estimation suggested that smoking effects
would be stronger at younger ages, possibly because the
smoke would induce mutations at relatively higher levels
than promotion of cell growth, compared with older age.
Table 1 Age and cumulative lung cancer mortality of
continuing and former smokers









75 (60) 9.9 70.22
75 (50) 6.0 66.27
75 (40) 3.0 61.72
75 (30) 1.7 58.37
aData from Doll et al. [20]
bThe corresponding continuing smoker’s age at which cumulative lung cancer
mortality risk is equal to the risk of that in former smokers at age 75 was
calculated from the quintic equationc which takes account of the risk in
continuing smokers. It is a simple technique and not dependent on the cancer
model. The difference between age 75 and the corresponding age is considered
to be “delayed effect on aging” by cessation of smoking (Fig. 1)
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Fig. 1 Estimation of the aging effects of smoking. Prolonged smoking
cessation resulted in a decreased relative risk of lung cancer mortality,
as exhibited by the “delayed effect on aging” (Table 1). The relationship
between the period of smoking cessation and the effect was plotted.
Linear regression yielded the equation y = 0.401x − 1.175. The coefficient
of the aging effect of smoking was 0.401/(1-0.401) = 0.669. This means
that smokers become old 1.669 times faster than nonsmokers. The lag
time between smoking and death was 1.175/0.401 = 2.93 years
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A good correlation was still observed by assuming a
higher starting age, and thus the age-specific cumulative
risks of former smokers were calculated using the equa-
tion and assuming a starting age of 18 years (Fig. 3). This
risk estimation accorded well with that estimated from the
relative risk of the period of smoking cessation [20].
Hence, the effects of the smoking habit may be roughly
approximated as an aging effect. Although the data used
in this study were from case–control studies combined
with national statistics [20], the relative risk of former
smokers according to the period of smoking cessation in a
variety of large cohort studies in the United States [24]
was similar to that of the case–control studies.
A report which analyzed three cohort studies in
Japanese subjects suggested that the risk of lung cancer
in former smokers decreased to the level in nonsmokers
after a long period of smoking cessation [30]. The reason
is unclear, but the relative risk of lung cancer in Japanese
subjects was lower than that in Caucasians [31, 32], and
the detection power was also lower. In addition, the
scale of the study was smaller than the cohort studies in
Caucasians, thus it is possible that a small difference in
risk between long-term quitters and nonsmokers could
not be detected.
Risk estimation - lesson from the smoking effect
When dose is represented by the number of cigarettes
per day rather than the duration of the smoking period,
approximately linear dose–response relationships are ob-
served in most studies [14–19]. This is in contrast to the
effect of smoking duration or aging. From the observa-
tion, it is possible that a dose–response relationship be-
tween smoking strength and each carcinogenic step,
such as initiation and promotion of cancer, is less than
linear, or the effects become saturated by a large amount
of daily smoking. Using data of large epidemiological
studies, the British Doctor Study, the American Cancer
Society’s Cancer Prevention Study I and II, the Nurses
Health Study and the Health Professionals Follow-Up
Study in a two-stage clonal expansion model, the
promotion rate powers were estimated to be around 0.5
[28, 29]. This means that the effects of smoking per dose
are relatively stronger at lower doses, i.e., second-hand
smoking or light smoking. The model simulation pro-
vides a different concept from that which suggests there
is a threshold for indirect carcinogens. However, it is
known that the effects of air pollution and second-hand
smoking on cardiovascular mortality per exposure dose
are higher than that of active smoking, which has an ap-
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Fig. 2 Cumulative lung cancer mortality risk of a nonsmoker and
continuing smoker. Data of risk were from Doll et al [20]. The continuing
smoker’s age corresponding to that of a nonsmoker was calculated
from the coefficient of the aging effect and the lag time (Fig. 1), and
age at starting smoking. a Smoking started at age 11; b Smoking
started at age 18. Solid line, nonsmoker; dashed line, continuing smoker.
It should be noted that these figures demonstrate the smoking effect as
additional aging effect during the smoking period and do not
predict the risk in a very old person. It is known that cancer risk in
the very old is often lower than that predicted by various cancer
models. The sextic regression equation obtained from the risk in a
nonsmoker and continuing smoker starting at age 18 together
was: y = − 5.096171 × 10− 10x6 + 1.983542 × 10− 7x5 − 3.006177 ×






















Fig. 3 Effect of smoking cessation at various ages on the cumulative
lung cancer mortality risk. A single polynomial regression equation
(Fig. 2) and age corresponding to a nonsmoker was used. The age
of starting smoking was assumed to be 18. The upper and lower
solid lines are the risks in continuing smokers and nonsmokers,
respectively. The dashed lines are the risks in former smokers who
stopped at age 60, 50, 40, and 30 years, from the higher to lower lines
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on the cardiovascular system such as oxidative stress,
vascular inflammation and dysfunction, activation of the
hemostatic system, and disturbance of autonomic ner-
vous system [34, 35], are suggested to be relatively
stronger at low doses. In addition, the relative effect of
second-hand smoking on lung cancer induction may
also be higher than that of active smoking [16, 36].
Therefore, the effects of smoking, such as cancer promo-
tion at low doses may be stronger per dose than at high
doses. This case clearly demonstrates the need for care-
ful examination of linear-no-threshold extrapolation as
the concept of the “safe side” of risk estimation.
Conclusion
Smoking is an additional burden on aging and death. It
is simple and useful approach to estimate lung cancer
risk from duration of smoking habit. Consideration of
the dose–response of each effect is important to evaluate
the risk arising from each carcinogenic factor including
tobacco smoke.
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